Zimmer Biomet Holdings Inc vs Zeta Global Holdings Corp — how do they compare? Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B), while Zeta Global Holdings Corp trades at $21.2 (market cap $5.32B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.3× Zeta Global Holdings Corp's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| ZBH | ZETA | |
|---|---|---|
Market Cap | $17.36B | $5.32B |
Sector | Health | Technology |
52-Week High | $107.71 | $25.24 |
52-Week Low | $79.58 | $14.55 |
Enterprise Value | $24.40B | $5.23B |
Dividend Yield | 1.07% | — |
Signals from Pluang's Aura AI — not financial advice
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Zeta Global (ZETA) trades at $21.34, down 1.57% on the day, with a neutral technical signal and bullish moving averages. The company reported strong revenue growth, with Q1 2026 EPS beating estimates, but remains unprofitable with a net margin of -1.61%. Recent news highlights a strategic AI partnership with Palantir, positioning Zeta for accelerated growth in marketing technology infrastructure.
The outlook is mixed: analyst consensus is strongly bullish with a $27.50 price target, but profitability concerns and margin pressure pose risks. The stock offers growth potential through AI adoption and partnerships, yet investors must weigh execution risks against transformative opportunities in a competitive sector.
Trailing returns across standard periods
Latest headlines on both assets
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →